[1]张涛元,丁雪梅,李 俏,等.人非小细胞肺癌组织中转录因子E2F 家族表达与临床病理特征及预后的相关性分析[J].现代检验医学杂志,2022,37(04):87-91.[doi:10.3969/j.issn.1671-7414.2022.04.017]
　ZHANG Tao-yuan,DING Xue-mei,LI Qiao,et al.Correlation Analysis of Transcription Factor E2F Family Expression with Clinicopathological Features and Prognosis in Human Non-small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2022,37(04):87-91.[doi:10.3969/j.issn.1671-7414.2022.04.017]
点击复制

人非小细胞肺癌组织中转录因子E2F 家族表达与临床病理特征及预后的相关性分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年04期
页码:
87-91
栏目:
论著
出版日期:
2022-07-15

文章信息/Info

Title:
Correlation Analysis of Transcription Factor E2F Family Expression with Clinicopathological Features and Prognosis in Human Non-small Cell Lung Cancer
文章编号:
1671-7414（2022）04-087-05
作者:
张涛元1; 丁雪梅2; 李 俏3; 祝撷英3; 曹三成3; 吴 爽3
1. 青岛大学附属日照医院/ 日照心脏病医院，山东日照 276801；2. 日照市中医医院，山东日照 276899；3. 西安交通大学附属儿童医院，西安 710003
Author(s):
ZHANG Tao-yuan1;  DING Xue-mei2;  LI Qiao3;  ZHU Xie-ying3;  CAO San-cheng3;  WU Shuang3
1. Affiliated Rizhao Hospital of Qingdao University /Rizhao International Heart Hospital, Shandong Rizhao 276801, China； 2.Rizhao Traditional Chinese Medicine Hospital, Shandong Rizhao 276899, China；3.the Affiliated Children Hospital of Xi’an Jiaotong University, Xi’an 710003,China
关键词:
E2F 家族; 非小细胞肺癌; 生物信息学
分类号:
R734.2；R730.43
DOI:
10.3969/j.issn.1671-7414.2022.04.017
文献标志码:
A
摘要:
目的 通过生物信息学技术分析转录因子E2F 家族在人非小细胞肺癌（non-small cell lung cancer，NSCLC）中的表达，探讨其与NSCLC 临床病理特征的关系，阐明E2F 家族对NSCLC 诊断及预后的影响。方法 使用Oncomine数据库、UALCAN 数据库分析E2F 家族在NSCLC 组织及正常肺组织中，mRNA 水平表达差异；利用UALCAN 及Kaplan Meier-Plotter 在线分析工具，阐明E2F 家族高表达与NSCLC 患者病理参数及患者总生存率(overall survival，OS) 之间的关系；并利用cBioPorta 网站分析E2F 家族在NSCLC 中的基因突变情况。结果 E2F 家族在NSCLC 中均呈现高表达，且与NSCLC 的肿瘤分级、淋巴转移相关；癌症基因组图谱(the cancer genome atlas, TCGA) 分析显示E2F1,E2F2, E2F4, E2F7 和E2F8 高表达与NSCLC 患者总生存率密切相关；突变分析显示，E2F 家族在NSCLC 中的突变率高达32%。结论 E2F 家族在NSCLC 中呈高表达，且与肿瘤的分级和淋巴转移呈正相关。
Abstract:
Objective To analyze the expression of transcription factor E2F family in human non-small cell lung cancer (NSCLC) by bioinformatics techniques,explore its relationship with clinicopathological features of NSCLC and clarify the influence of E2F family on the diagnosis and prognosis of NSCLC. Methods Oncomine database and UALCAN database were used to analyze the mRNA expression differences of E2F family in NSCLC tissues and normal lung tissues. UALCAN and Kaplan Meier- Plotter online analysis tools were used to clarify the relationship between the high expression of E2F family and the pathological parameters and overall survival(OS) rate of NSCLC patients. The E2F family gene mutation in NSCLC was analyzed by cBioPorta website. Results E2F family was highly expressed in NSCLC, and was correlated with tumor grade and lymphatic metastasis of NSCLC.TCGA(the cancer genome atlas) analysis showed that the high expression of E2F1,E2F2,E2F4,E2F7 and E2F8 was closely related to the overall survival rate of NSCLC patients. Mutation analysis showed that the mutation rate of E2F family in NSCLC was up to 32%. Conclusion E2F family was highly expressed in NSCLC, and was positively correlated with tumor grade and lymphatic metastasis。

参考文献/References:

[1] FANG Jing, SUN Chengcao, GONG Cheng. Long noncoding RNA XIST acts as an oncogene in non-small cell lung cancer by epigenetically repressing KLF2 expression[J]. Biochemical and Biophysical Research Communications, 2016, 478(2): 811-817.
[2] SUN Chengcao, LI Shujun, LI Dejia. Hsa-miR-134 suppresses non-small cell lung cancer (NSCLC) development through down-regulation of CCND1[J].Oncotarget, 2016, 7(24): 35960-35978.
[3] SUN Chengcao, HUANG Chuanfeng, LI Shujun, et al.Hsa-miR-326 targets CCND1 and inhibits non-small cell lung cancer development[J]. Oncotarget, 2016,7(7): 8341-8359.
[4] CHEN Li, YU Jianhua, LU Zhihui, et al. E2F2 induction in related to cell proliferation and poor prognosis in non-small cell lung carcinoma[J].International Journal of Clinical and Experimental Pathology, 2015, 8(9): 10545-10554.
[5] PARK S A, PLATT J, LEE J W, et al. E2F8 as a novel therapeutic target for lung cancer[J]. Journal of the National Cancer Institute, 2015, 107(9): djv151.
[6] COOPER C S, NICHOLSON A G, FOSTER C A, et al.Nuclear overexpression of the E2F3 transcription factor in human lung cancer[J]. Lung Cancer, 2006, 54(2):155-162.
[7] LI Zunling, JIAO Fei, MA Ying, et al. Target genes regulated by transcription factor E2F1 in small cell lung cancer[J]. Acta Physiologica Sinica, 2016, 68(3): 276-284.
[8] RHODES D R, YU Jianjun, SHANKER K, et al.ONCOMINE: a cancer microarray database and integrated data-mining platform[J]. Neoplasia (New York, N.Y.), 2004, 6(1): 1-6.
[9] CHANDRASHEKAR D S, BASHEL B, BALASUBRAMANYA S A, et al. UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses[J]. Neoplasia (New York, N.Y.), 2017, 19(8):649-658.
[10] TANG Zefang, LI Chenwei, KANG Boxi, et al. GEPIA:a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Research, 2017, 45(W1): W98-W102.
[11] FRANCESCHINI A, SZKLARCZYK D, FRANKILD S, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration[J].Nucleic Acids Research, 2013, 41(Database issue):D808-D815.
[12] SMOOT M E, ONO K, RUSCHEINSKI J, et al.Cytoscape 2.8: new features for data integration and network visualization[J]. Bioinformatics (Oxford,England), 2011, 27(3): 431-432.
[13] TIMMERS C, SHARMA N, OPAVSKY R, et al.E2F1,E2F2,and E2F3 control E2F target expression and cellular proliferation via a p53-dependent negative feedback loop[J]. Molecular and Cellular Biology,2007, 27(1): 65-78.
[14] CHEN Huizi, TSAI S Y, LEONE G. Emerging roles of E2Fs in cancer: an exit from cell cycle control[J].Nature Reviews Cancer, 2009, 9(11): 785-797.
[15] LIANG Yuxiang, LU Jianming, MO Rujun, et al. E2F1 promotes tumor cell invasion and migration through regulating CD147 in prostate cancer[J]. International Journal of Oncology, 2016, 48(4): 1650-1658.
[16] GORGOULIS V G, ZACHARATOS P, MARIATOS G, et al. Transcription factor E2F-1 acts as a growthpromoting factor and is associated with adverse prognosis in non-small cell lung carcinomas[J]. The Journal of Pathology, 2002, 198(2): 142-156.
[17] FELICIANO A, GARCIA-MAYEA Y, JUBIERRE L, et al. MiR-99a reveals two novel oncogenic proteins E2F2 and EMR2 and represses stemness in lung cancer[J].Cell Death & Disease, 2017, 8(10): e3141.
[18] TRIKHA P, SHARMA N, PENA C, et al. E2F3 in tumor macrophages promotes lung metastasis[J].Oncogene, 2016, 35(28): 3636-3646.
[19] WU Lei, WAN Shan, LI Jinfan, et al. Expression and prognostic value of E2F3 transcription factor in nonsmall cell lung cancer[J]. Oncology Letters, 2021,21(5): 411.
[20] SCHWEMMLE S, PFEIFER G P. Genomic structure and mutation screening of the E2F4 gene in human tumors[J]. International Journal of Cancer, 2000, 86(5):672-677.
[21] BANKOVIC J, STOJSIC J, JOVANOVIC D, et al.Identification of genes associated with non-smallcell lung cancer promotion and progression [J]. Lung Cancer (Amsterdam, Netherlands), 2010, 67(2): 151-159.
[22] FANG D Z, WANG Y P, LIU J, et al. MicroRNA-129-3p suppresses tumor growth by targeting E2F5 in glioblastoma[J]. European Review for Medical and Pharmacological Sciences, 2018, 22(4): 1044-1050.
[23] LI Shunlai, SUI Ying, SUN Jie, et al. Identification of tumor suppressive role of microRNA-132 and its target gene in tumorigenesis of prostate cancer[J].International Journal of Molecular Medicine, 2018,41(4): 2429-2433.
[24] LAMMENS T, LI J, LEONE G, et al. Atypical E2Fs:New players in the E2F transcription factor family[J].Trends in Cell Biology, 2009, 19(3): 111-118.
[25] DENG Qing, WANG Qun, ZONG Weiying, et al. E2F8 contributes to human hepatocellular carcinoma via regulating cell proliferation[J]. Cancer Research, 2010,70(2): 782-791.
[26] WEIJTS B G, BAKKER W J, CORNELISSEN P W,et al. E2F7 and E2F8 promote angiogenesis through transcriptional activation of VEGFA in cooperation with HIF1[J]. The EMBO Journal, 2012, 31(19): 3871-3884.

相似文献/References:

[1]张 蕾,任亚女,曾婷婷,等.晚期非小细胞肺癌患者血液实验指标和病理分期等因素对生存时间的影响分析[J].现代检验医学杂志,2016,31(02):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
　ZHANG Lei,REN Ya-n,ZENG Ting-ting,et al.Analysis of Prognosis Related Factors in Patients with Advanced Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(04):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
[2]薛鸿涛,任 敏,李长彬.非小细胞肺癌患者放疗前后血清TSGF和CRP的变化及其临床意义[J].现代检验医学杂志,2016,31(02):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
　XUE Hong-tao,REN Min,LI Chang-bin.Impact and Clinical Significance of Radiotherapy on Serum TSGF and CRP in Patients with Non Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(04):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
[3]王京伟,李 艳,童永清,等.湖北地区非小细胞肺癌EGFR 基因突变及其意义的研究[J].现代检验医学杂志,2016,31(03):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
　WANG Jing-wei,LI Yan,TONG Yong-qing,et al.Detection of Epidermal Growth Factor Receptor(EGFR) Mutations and the Significance in Patients with Non-small Cell Lung Cancer(NSCLC)of Hubei Province[J].Journal of Modern Laboratory Medicine,2016,31(04):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
[4]易甲其,范艳平,周宁加,等.血清PTX-3，CYFRA21-1和TPS在非小细胞肺癌中的变化及临床意义[J].现代检验医学杂志,2015,30(05):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
　YI Jia-qi,FAN Yan-ping,ZHOU Ning-jia,et al.Changes and Clinical Significance of Serum PTX-3， CYFRA21-1，TPS in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2015,30(04):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
[5]钱忠萍,凌 晨,祁松楠,等.围非小细胞肺癌手术期T细胞含量变化的研究[J].现代检验医学杂志,2016,31(05):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
　QIAN Zhong-ping,LING Chen,QI Song-nan,et al.Content Variation of T Cells in Perioperative Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(04):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
[6]黎谢梦丹,罗 凯,吴顺芳,等.华南地区非小细胞肺癌患者肿瘤组织EGFR,ALK和ROS1基因突变分析[J].现代检验医学杂志,2017,32(05):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]
　LIXIE Meng-dan,LUO Kai,WU Shun-fang,et al.Mutation Analysis of EGFR,ALK and ROS1 in Tumor Tissues of Patients with Non-Small Cell Lung Cancer in South of China[J].Journal of Modern Laboratory Medicine,2017,32(04):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]
[7]李小龙,白巧艳,陆婉玲.老年非小细胞肺癌患者低分割放疗对凝血功能的影响[J].现代检验医学杂志,2018,33(05):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
　LI Xiao-long,BAI Qiao-yan,LU Wan-ling.Influence of Hypofractionated High-Dose Radiotherapy on Coagulation Function in Elderly Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(04):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
[8]郭 华a,齐宗利a,张海祥b,等.非小细胞肺癌组织EGFR/ALK/ROS1基因联合检测的临床意义[J].现代检验医学杂志,2018,33(06):17.[doi:10.3969/j.issn.1671-7414.2018.06.005]
　GUO Huaa,QI Zong-lia,ZHANG Hai-xiangb,et al.Clinical Significance of Combined Detection of EGFR/ALK/ROS1 Genes in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(04):17.[doi:10.3969/j.issn.1671-7414.2018.06.005]
[9]黄 刚,陈 霏,肇玉博,等.非小细胞肺癌患者血浆miRNA-145和miRNA-221表达与临床特征及术后复发的相关性研究[J].现代检验医学杂志,2019,34(04):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
　HUANG Gang,CHEN Fei,ZHAO Yu-bo,et al.Study on the Correlation between the Expression of MicroRNA145 and MicroRNA221 in Plasma and Clinical Characteristics and Postoperative Recurrence in Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2019,34(04):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
[10]蒋玲丽,黄中强,王雪亮,等.表皮生长因子受体（EGFR）基因突变检测质控品制备及应用[J].现代检验医学杂志,2020,35(02):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]
　JIANG Ling-li,HUANG Zhong-qiang,WANG Xue-liang,et al.Development and Application of Quality Control Materials for EpidermalGrowth Factor Receptor （EGFR）Mutation Determination[J].Journal of Modern Laboratory Medicine,2020,35(04):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]

备注/Memo

备注/Memo:
基金项目： 陕西省社会发展科技攻关项目（NO.2016SF-036）；西安交通大学基本科研业务费自由探索与创新-教师类项目（NO.xzyo12019129）。
作者简介：张涛元（1987-），男，硕士，主治医师，研究方向：器官保护、肺保护，E-mail: 1250424266@qq.com。
通讯作者：吴爽，女，硕士，主管检验技师，研究方向：基因甲基化在儿童哮喘中介导气道炎症及重塑的机制研究。
更新日期/Last Update: 1900-01-01